October, 2016

Pain and Addiction: a solution to the opioid epidemic. By Brian Kobilka Watch on YouTube »

February, 2016

ConfometRx unlocks novel GPCR-G protein structure within UCB research collaboration. We are pleased to announce that it has succeeded in elucidating the crystallographic structure of a novel GPCR-G protein complex composed of a Family A GPCR coupled to its G protein, only the second reported GPCR-G protein complex. More »

August, 2015

Awarded a 3-year SBIR phase 1 & 2 grant for Developing Methods in Crystallizing and Drug Discovery for a Family B GPCR.

May, 2014

The structure of A2A Adenosine receptor bound to a novel antagonist was solved in collaboration with UCB Pharma.

February, 2013

ConfometRx and UCB Announce New R&D Partnership. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs. More »

October, 2012

Brian Kobilka, co-founder, was awarded the Nobel Prize in Chemistry. His co-recipient is Robert Lefkowitz of Duke University. More »

August 2012

Awarded a 3-year SBIR phase 2 grant for Developing Methods in Crystallizing a Family C GPCR.

August 2012

Established a collaboration with Bristol-Myers Squibb Company to obtain crystal structures of a G-protein coupled receptor to enable discovery of novel medicines for unmet medical needs.

December 2011

The structure of M1 muscarinic receptor bound to an antagonist was solved.

September 2011

Confometrx signed a multi-year collaborative agreement with Novo Nordisk A/S of Denmark to obtain crystal structures of a GPCR. Combining the extensive expertise of both companies, the goal is to discover newer and better therapeutic agents.

February 2010

Awarded a 2-year SBIR phase 1 grant for Developing Methods in Crystallizing a Family C GPCR.

July 2009

Awarded phase 1 SBIR grant for Developing Methods for Crystallizing Family B GPCRs.

April 2008

Established a multi-year collaboration with Bristol-Myers Squibb Company to obtain crystal structures of G-protein coupled receptors to enable discovery of novel medicines for unmet medical needs.

December 2007

Lundbeck A/S Signed a collaborative agreement with Lundbeck A/S of Denmark whereby ConfometRx, Inc will obtain crystal structures of two G-protein coupled receptors for Lundbeck A/S. The agreement is based on upfront and milestone payments.

November 2006

Work on the second target from Medarex was initiated.

March 2006

Awarded Phase I SBIR Grant to develop a flourescent screening assay based on ConfoTeG technology.

August 2005

ConfometRx has entered into a partnership with Medarex, Inc. to generate novel immunogens. We are providing Medarex with high-quality protein preparations produced using our proprietary technology for membrane-associated protein expression and purification.